1. Home
  2. USBC vs ALDX Comparison

USBC vs ALDX Comparison

Compare USBC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USBC Inc.

USBC

USBC Inc.

N/A

Current Price

$0.69

Market Cap

333.2M

Sector

N/A

ML Signal

N/A

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$5.30

Market Cap

293.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USBC
ALDX
Founded
N/A
2004
Country
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.2M
293.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
USBC
ALDX
Price
$0.69
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.50
AVG Volume (30 Days)
N/A
1.6M
Earning Date
N/A
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$36.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.14
52 Week High
N/A
$7.20

Technical Indicators

Market Signals
Indicator
USBC
ALDX
Relative Strength Index (RSI) 40.94 53.77
Support Level $0.68 $4.98
Resistance Level $0.74 $5.75
Average True Range (ATR) 0.06 0.47
MACD -0.00 0.07
Stochastic Oscillator 10.04 75.07

Price Performance

Historical Comparison
USBC
ALDX

About USBC USBC Inc.

USBC Inc is a non-invasive medical diagnostics. The group is focused on the development and commercialization of proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Its Sensor technology elicits a dielectric response that is different for every molecule. The group considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology, with a first focus on non-invasively ascertaining blood glucose levels.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: